Posted by Michael Wonder on 12 Oct 2023
Health economic assessment of the gene therapy Hemgenix in severe and moderate haemophilia B
11 October 2023 - TLV has developed a health economic knowledge base for the regions for the gene therapy Hemgenix (etranacogene dezaparvovec), which is intended for the treatment of severe and moderate haemophilia B (congenital factor IX deficiency) in adult patients without a history of disease with factor IX antibodies that inhibit the effect of coagulation factor IX.
The company's price for Hemgenix is approximately SEK 29.3 million for a one-time treatment. To this is added an administration cost and costs for follow-up.
